Literature DB >> 31215017

Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database.

Mark B Ulanja1, Mohit Rishi2, Bryce D Beutler2, Kenneth G Konam3, Santhosh Ambika2,4, Tomas Hinojosa5, Francis T Djankpa6, Wei Yang7, Nageshwara Gullapalli2.   

Abstract

BACKGROUND: Gastrointestinal tumors (GISTs) represent the most common mesenchymal tumors of the gastrointestinal tract. There has been limited data on GIST incidence and survival disparities between ethnic groups. AIMS: Assess disparities in incidence and survival among race in the USA in the era of available GIST histologic codes and treatment.
METHODS: We queried Surveillance, Epidemiology, and End Results (SEER) database for GIST from 2002 to 2015, with diagnostic code 8936.
RESULTS: Of the 7204 patients identified, 4928 (68.4%) were White, 1308 (18.2%) African American (AA), and 968 (13.4%) were classified as "Other" (American Indian/Alaskan Native, Asian/Pacific Islander). The overall incidence rate (IR) was 0.75 per 100,000. IR was highest among AA at 1.37/100,000, but 0.65/100,000 for Whites, 1.10/100,000 for Asians/Pacific Islanders, and 0.28/100,000 for American Indians/Alaskan Natives. The GIST incidence was twice as high for AA as for Whites (rate ratio [RR]: 2.12; 95% CI: 1.98-2.26; p < 0.001). There was higher proportion of Whites than AA, who underwent surgical extirpation. Median overall survival (OS) and GIST specific survival (GSS) were not reached for all race, which indicates more than half of the patients were still alive at end of follow-up period. In multivariate Cox model, belonging to "Other" had better OS (adjusted hazard ratio [aHR]; 0.73, 95% CI: 0.55-0.95, P = 0.021) for GIST, but no difference in prognosis and OS for AA and White [(aHR for whites; 0.84, 95% CI: 0.69-1.02, P = 0.071), AA = reference]. There was no difference in GSS among races.
CONCLUSIONS: Significant racial disparity in incidence and overall survival for GIST exists, and efforts should be made to bridge this gap and improve outcomes for all races. The overall incidence rate for GIST was noted to be 7.5 per 1 million, and IR of GIST was twice as high for African Americans as compared to Whites. The "Other" racial group (American Indians/Alaskan Natives, Asians, and Pacific Islanders) had superior OS as compared to African Americans and Whites.

Entities:  

Keywords:  Gastrointestinal stromal tumors; Incidence of GIST; Incidence rate; Median survival; Race disparity; Surveillance epidemiology and end results

Year:  2019        PMID: 31215017     DOI: 10.1007/s40615-019-00605-9

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  35 in total

1.  Poverty, culture, and social injustice: determinants of cancer disparities.

Authors:  Harold P Freeman
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Epidemiology of GIST.

Authors:  Charles Blanke; Burton L Eisenberg; Michael Heinrich
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

4.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

5.  The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

Authors:  Thomas Tran; Jessica A Davila; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

6.  Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.

Authors:  Markku Miettinen; John F Fetsch; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-01       Impact factor: 6.394

7.  Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

Authors:  Geir Tryggvason; Hjörtur G Gíslason; Magnús K Magnússon; Jón G Jónasson
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

8.  State-specific prevalence of selected health behaviors, by race and ethnicity--Behavioral Risk Factor Surveillance System, 1997.

Authors:  J C Bolen; L Rhodes; E E Powell-Griner; S D Bland; D Holtzman
Journal:  MMWR CDC Surveill Summ       Date:  2000-03-24

9.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

Review 10.  Diagnosis of gastrointestinal stromal tumors: a consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Int J Surg Pathol       Date:  2002-04       Impact factor: 1.271

View more
  6 in total

1.  Upper Gastrointestinal Cancer: Delays in Diagnosis and Treatment Caused by Barriers to Healthcare in the Latino Community.

Authors:  Eleazar E Montalvan-Sanchez; Renato Beas; Dalton Argean Norwood; Ahmad Mahmoud Alkashash; Aida A Rodriguez Murillo; Gerardo Calderon
Journal:  Gastroenterology Res       Date:  2022-06-16

2.  Changing Disparity of Gastric Cancer Incidence by Histological Types in US Race-Specific Populations.

Authors:  Xuan Zhu; Alessio Pigazzi; Jason Zell; Yunxia Lu
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

3.  A rare rectal gastrointestinal stromal tumor with indolent biological behavior: A case study.

Authors:  Jian Yang; Ying Liu; Xue-Jia Sun; Zhong-Wei Ai; Shi Liu
Journal:  Exp Ther Med       Date:  2022-08-30       Impact factor: 2.751

4.  Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study.

Authors:  Weihao Li; Xinyue Li; Kun Yu; Binyi Xiao; Jianhong Peng; Rongxin Zhang; Lingfang Zhang; Kun Wang; Zhizhong Pan; Cong Li; Xiaojun Wu
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

5.  Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center.

Authors:  Zifeng Yang; Wentai Guo; Rongkang Huang; Minhui Hu; Huaiming Wang; Hui Wang
Journal:  Ann Transl Med       Date:  2020-03

6.  The Combination of Neoadjuvant Therapy and Surgical Resection: A Safe and Effective Treatment for Rectal Gastrointestinal Stromal Tumors.

Authors:  Yu Liu; Wenju Chang; Wentao Tang; Ye Wei; Tianyu Liu; Yijiao Chen; Meiling Ji; Fei Liang; Li Ren; Jianmin Xu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.